These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 4472237)

  • 21. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S
    Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
    [No Abstract]   [Full Text] [Related]  

  • 22. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.
    Lees AJ; Shaw KM; Stern GM
    Lancet; 1977 Nov; 2(8046):1034. PubMed ID: 72935
    [No Abstract]   [Full Text] [Related]  

  • 23. The "on-off" side effect of L-DOPA.
    Markham CH
    Adv Neurol; 1974; 5():387-96. PubMed ID: 4440586
    [No Abstract]   [Full Text] [Related]  

  • 24. Protein intake and treatment of Parkinson's disease with levodopa.
    Mena I; Cotzias GC
    N Engl J Med; 1975 Jan; 292(4):181-4. PubMed ID: 1109209
    [No Abstract]   [Full Text] [Related]  

  • 25. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 26. Variations in the "on-off" phenomenon.
    Duvoisin RC
    Adv Neurol; 1974; 5():339-40. PubMed ID: 4440582
    [No Abstract]   [Full Text] [Related]  

  • 27. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
    Schuh LA; Bennett JP
    Neurology; 1993 Aug; 43(8):1545-50. PubMed ID: 8351009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusaric acid in Parkinson's disease.
    Chase TN
    Neurology; 1974 Jul; 24(7):637-9. PubMed ID: 4858086
    [No Abstract]   [Full Text] [Related]  

  • 29. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
    Barbeau A; Roy M
    Neurology; 1976 May; 26(5):399-404. PubMed ID: 944392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Problems in the administration of L-DOPA (author's transl)].
    Ferrari E
    Riv Patol Nerv Ment; 1974 Aug; 95(4):239-50. PubMed ID: 4283417
    [No Abstract]   [Full Text] [Related]  

  • 31. [Biochemical and clinical correlations in Parkinson's disease].
    Barbeau A
    Rev Neurol (Paris); 1972 Aug; 127(2):253-64. PubMed ID: 4603361
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter: Dyskinesias during levodopa therapy.
    Tolosa ES; Maritn WE; Cohen HP
    Lancet; 1975 Jun; 1(7921):1381-2. PubMed ID: 48968
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
    Przuntek H; Kuhn W
    Adv Neurol; 1990; 53():445-9. PubMed ID: 1700583
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
    Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
    Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The current treatment of Parkinson's disease].
    Gonce M; Barbeau A
    Rev Med Liege; 1976 Oct; 31(19):563-73. PubMed ID: 790511
    [No Abstract]   [Full Text] [Related]  

  • 36. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetrahydrobiopterin and Parkinson's disease.
    Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
    Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of plasma concentrations of levodopa to clinical response in Parkinsonsim.
    Allen JG; Calne DB; Davies CA; Reid JL
    Br J Pharmacol; 1971 Oct; 43(2):464P-465P. PubMed ID: 5158238
    [No Abstract]   [Full Text] [Related]  

  • 39. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 40. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C; Asper R; Baumgartner G
    Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.